Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Celldex Therapeutics, Inc is a biotechnology business based in the US. Celldex Therapeutics shares (CLDX) are listed on the NASDAQ and all prices are listed in US Dollars. Celldex Therapeutics employs 127 staff and has a trailing 12-month revenue of around USD$4.5 million.
|52-week range||USD$1.5 - USD$30.17|
|50-day moving average||USD$22.8368|
|200-day moving average||USD$17.7946|
|Wall St. target price||USD$34.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.741|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$4.5 million|
|Gross profit TTM||USD$-39,099,000|
|Return on assets TTM||-16.76%|
|Return on equity TTM||-29.17%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 3.4 million Celldex Therapeutics shares held short by investors – that's known as Celldex Therapeutics's "short interest". This figure is 2.1% down from 3.5 million last month.
There are a few different ways that this level of interest in shorting Celldex Therapeutics shares can be evaluated.
Celldex Therapeutics's "short interest ratio" (SIR) is the quantity of Celldex Therapeutics shares currently shorted divided by the average quantity of Celldex Therapeutics shares traded daily (recently around 609028.49557522). Celldex Therapeutics's SIR currently stands at 5.65. In other words for every 100,000 Celldex Therapeutics shares traded daily on the market, roughly 5650 shares are currently held short.
However Celldex Therapeutics's short interest can also be evaluated against the total number of Celldex Therapeutics shares, or, against the total number of tradable Celldex Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celldex Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Celldex Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.087% of the tradable shares (for every 100,000 tradable Celldex Therapeutics shares, roughly 87 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Celldex Therapeutics.
Find out more about how you can short Celldex Therapeutics stock.
We're not expecting Celldex Therapeutics to pay a dividend over the next 12 months.
Celldex Therapeutics's shares were split on a 1:15 basis on 11 February 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Celldex Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Celldex Therapeutics shares which in turn could have impacted Celldex Therapeutics's share price.
Over the last 12 months, Celldex Therapeutics's shares have ranged in value from as little as $1.5 up to $30.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celldex Therapeutics's is 2.706. This would suggest that Celldex Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Everything we know about the Reddit IPO, plus information on how to buy in.
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
Everything we know about the Procore IPO, plus information on how to buy in.
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Bukalapak IPO, plus information on how to buy in.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.